CN117088982A - Anti-methamphetamine antibodies, reagents and kits for detecting methamphetamine - Google Patents

Anti-methamphetamine antibodies, reagents and kits for detecting methamphetamine Download PDF

Info

Publication number
CN117088982A
CN117088982A CN202210509727.7A CN202210509727A CN117088982A CN 117088982 A CN117088982 A CN 117088982A CN 202210509727 A CN202210509727 A CN 202210509727A CN 117088982 A CN117088982 A CN 117088982A
Authority
CN
China
Prior art keywords
ser
thr
val
antibody
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202210509727.7A
Other languages
Chinese (zh)
Inventor
孟媛
钟冬梅
曹慧方
游辉
覃文新
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dongguan Pengzhi Biotechnology Co Ltd
Original Assignee
Dongguan Pengzhi Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dongguan Pengzhi Biotechnology Co Ltd filed Critical Dongguan Pengzhi Biotechnology Co Ltd
Priority to CN202210509727.7A priority Critical patent/CN117088982A/en
Publication of CN117088982A publication Critical patent/CN117088982A/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

The application discloses an anti-methamphetamine antibody, a reagent and a kit for detecting methamphetamine, and relates to the technical field of antibodies. The anti-methamphetamine antibodies disclosed herein include a heavy chain complementarity determining region and a light chain complementarity determining region. The antibody provides an important raw material source for detecting methamphetamine, and has improved affinity and activity.

Description

Anti-methamphetamine antibodies, reagents and kits for detecting methamphetamine
Technical Field
The application relates to the technical field of antibodies, in particular to an anti-methamphetamine antibody, a reagent for detecting methamphetamine and a kit.
Background
Methamphetamine (MET), also known as Methamphetamine, having a chemical formula of C10H15N (N-methyl-1-phenylpropan-2-amine, N-methyl- α -methylphenylamine), which is commonly known as glacial venom, is administered orally, by inhalation, by direct nasal inhalation, by intravenous injection, etc., and has high bioavailability, is a potent central nervous system stimulant, and is mainly used as a drug. Methamphetamine was found in 1893 as two enantiomers: respectively, levo-methamphetamine and dextro-methamphetamine.
Methamphetamine is an indirect agonist of dopamine and norepinephrine in the central nervous system, and long-term intake of methamphetamine can cause brain dysfunction, and psychotic symptoms such as auditory hallucination, abnormal hyperreactivity, harmful delusions, cognitive dysfunction and the like appear. On the other hand, methamphetamine produces a range of physiological effects, primarily by indirectly stimulating neurotransmitters, causing damage to neurons, also making methamphetamine abusable and difficult to break. In view of the human body harm and social harm of methamphetamine, methamphetamine is listed as a controlled drug in China and cannot be abused. The quick detection method of methamphetamine is established, has important significance for striking crimes and preventing drug administration, and meets the requirements of special high-risk occupational toxicity-related safety physical examination.
At present, the detection method of methamphetamine mainly comprises a colloidal gold immunochromatography method, has the advantages of rapidness, simplicity in operation and the like, is an immunological detection method based on the specific reaction of antibodies and antigens, and simultaneously utilizes colloidal gold to amplify and display detected signals, and the obtained anti-MET antibodies are key to developing colloidal gold immunochromatography test paper. Thus, there is a strong need in the art for antibodies that bind effectively to methamphetamine and detect it.
In view of this, the present application has been made.
Disclosure of Invention
The application provides an anti-methamphetamine antibody with improved affinity and/or activity, so as to improve detection of methamphetamine, and provide an important raw material source for detection of methamphetamine.
In order to achieve the above object, according to one aspect of the present application, there is provided an antibody or a functional fragment thereof comprising HCDR1 having an amino acid sequence shown in SEQ ID NO. 1, HCDR2 having an amino acid sequence shown in SEQ ID NO. 2 or 15, HCDR3 having an amino acid sequence shown in SEQ ID NO. 3, and LCDR1 having an amino acid sequence shown in SEQ ID NO. 4, LCDR2 having an amino acid sequence shown in SEQ ID NO. 5, LCDR3 having an amino acid sequence shown in SEQ ID NO. 6.
In order to achieve the above object, according to a second aspect of the present application, there is provided an anti-methamphetamine antibody or a functional fragment thereof, which comprises a heavy chain variable region comprising the sequence structure of HFR1-HCDR1-HFR2-HCDR2-HFR3-HCDR3-HFR4 and/or a light chain variable region comprising the sequence structure of LFR1-LCDR1-LFR2-LCDR2-LFR3-LCDR3-LFR4, wherein the amino acid sequence of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3 is the amino acid sequence of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3 described above.
In order to achieve the above object, according to a third aspect of the present application, there is provided an anti-methamphetamine antibody comprising a heavy chain variable region as described above and/or a light chain comprising a light chain variable region as described above.
In order to achieve the above object, according to a fourth aspect of the present application, there is provided an antibody conjugate comprising the above antibody or a functional fragment thereof.
In order to achieve the above object, according to a fifth aspect of the present application, there is provided a reagent or kit for detecting methamphetamine, the reagent or kit comprising the above antibody or a functional fragment thereof or the above antibody conjugate.
In order to achieve the above object, the present application also provides a vector, a cell and a method for preparing the above antibody or a functional fragment thereof.
Drawings
In order to more clearly illustrate the technical solutions of the embodiments of the present application, the drawings that are needed in the embodiments will be briefly described below, it being understood that the following drawings only illustrate some embodiments of the present application and therefore should not be considered as limiting the scope, and other related drawings may be obtained according to these drawings without inventive effort for a person skilled in the art.
FIG. 1 shows the results of reducing SDS-PAGE of Anti-MET-19G8mut1 to Anti-MET-19G8mut5.
Detailed Description
The application provides an antibody or a functional fragment thereof, which comprises HCDR1 with an amino acid sequence shown as SEQ ID NO. 1, HCDR2 with SEQ ID NO. 2 or 15, HCDR3 with SEQ ID NO. 3, and LCDR1 with an amino acid sequence shown as SEQ ID NO. 4, LCDR2 with SEQ ID NO. 5 and LCDR3 with SEQ ID NO. 6. The antibodies have improved affinity and/or activity.
In the present application, the term "antibody" is used in the broadest sense and may include full length monoclonal antibodies, bispecific or multispecific antibodies, and chimeric antibodies so long as they exhibit the desired biological activity.
In the present application, the terms "complementarity determining regions", "CDRs" or "CDRs" refer to the highly variable regions of the heavy and light chains of immunoglobulins, and refer to regions comprising one or more or even all of the major amino acid residues responsible for the binding of an antibody or antigen-binding fragment to the antigen or epitope recognized by it. In a specific embodiment of the application, CDRs refer to the highly variable regions of the heavy and light chains of the antibody.
In the present application, the heavy chain complementarity determining region is represented by HCDR, which includes HCDR1, HCDR2 and HCDR3; the light chain complementarity determining regions are denoted by LCDR and include LCDR1, LCDR2 and LCDR3. CDR labeling methods commonly used in the art include: the Kabat numbering scheme, the IMGT numbering scheme, the Chothia and Lesk numbering schemes, and the 1997 Lefranc et al, all protein sequences of the immunoglobulin superfamily. Kabat et al were the first to propose a standardized numbering scheme for immunoglobulin variable regions. Over the past few decades, the accumulation of sequences has led to the creation of Kabat numbering schemes, which are generally considered as widely adopted criteria for numbering antibody residues. The application adopts Kabat annotation standard to mark CDR regions, but other methods to mark CDR regions also belong to the protection scope of the application.
In the present application, a "framework region" or "FR" region includes a heavy chain framework region and a light chain framework region, and refers to regions other than CDRs in an antibody heavy chain variable region and a light chain variable region; wherein the heavy chain framework regions can be further subdivided into contiguous regions separated by CDRs comprising HFR1, HFR2, HFR3 and HFR4 framework regions; the light chain framework regions may be further subdivided into contiguous regions separated by CDRs comprising LFR1, LFR2, LFR3 and LFR4 framework regions.
In the present application, the heavy chain variable region is obtained by connecting the following numbered CDRs with FRs in the following combination arrangement: HFR1-HCDR1-HFR2-HCDR2-HFR3-HCDR3-HFR4; the light chain variable region is obtained by ligating the following numbered CDRs with the FR in the following combination arrangement: LFR1-LCDR1-LFR2-LCDR2-LFR3-LCDR3-LFR4.
In alternative embodiments, the antibody or functional fragment thereof further comprises HFR1, HFR2, HFR3, HFR4 having amino acid sequences shown in SEQ ID NO. 7 through SEQ ID NO. 10, and LFR1, LFR2, LFR3 and LFR4 having amino acid sequences shown in SEQ ID NO. 11 through SEQ ID NO. 14.
In other embodiments, each of the framework amino acid sequences of the antibodies or functional fragments thereof provided herein may have at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% homology to the corresponding framework region (SEQ ID NO:7, 8, 9, 10, 11, 12, 13 or 14) described above.
In an alternative embodiment, the antibody or functional fragment thereof has a KD of 4.83×10 or less -7 M binds methamphetamine with affinity.
In an alternative embodiment, the antibody or functional fragment thereof has a KD of 10 or less -7 M、KD≤10 -8 M、KD≤10 - 9 M、KD≤10 -10 M、KD≤10 -11 M binds methamphetamine with affinity.
In an alternative embodiment, the antibody or functional fragment thereofWith KD less than or equal to 5.12X10 -8 M binds methamphetamine with affinity.
In an alternative embodiment, the amino acid sequence of HFR3 of the antibody or functional fragment thereof is set forth in SEQ ID NO. 16.
In an alternative embodiment, the amino acid sequence of LFR1 of said antibody or functional fragment thereof is shown in SEQ ID NO. 17.
In another aspect, embodiments of the present application provide an antibody or a functional fragment thereof against methamphetamine, the antibody or the functional fragment thereof comprises a heavy chain variable region comprising the sequence structure of HFR1-HCDR1-HFR2-HCDR2-HFR3-HCDR3-HFR4 and/or a light chain variable region comprising the sequence structure of LFR1-LCDR1-LFR2-LCDR2-LFR3-LCDR3-LFR4, wherein the amino acid sequence of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3 is the amino acid sequence of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3, wherein the amino acid sequence of HFR1, HFR2, HFR3, HFR4, LFR1, HFR2, LFR3, LFR4 is the amino acid sequence of HFR1, HFR2, HFR3, LFR4, LFR2, LFR4.
In an alternative embodiment, the heavy chain variable region amino acid sequence is set forth in any one of SEQ ID NOs 20 to 23.
In an alternative embodiment, the light chain variable region amino acid sequence is set forth in any one of SEQ ID NOs 24 to 25.
In alternative embodiments, the antibody further comprises a constant region.
In alternative embodiments, the constant region comprises a heavy chain constant region and/or a light chain constant region.
In alternative embodiments, the heavy chain constant region is selected from the group consisting of an IgG1, igG2, igG3, igG4, igA, igM, igE, or IgD heavy chain constant region, and the light chain constant region is selected from the group consisting of kappa-type or lambda-type light chain constant regions.
In alternative embodiments, the constant region is of a species derived from a cow, horse, cow, pig, sheep, rat, mouse, dog, cat, rabbit, donkey, deer, mink, chicken, duck, goose, turkey, chicken, or human.
In an alternative embodiment, the constant region is of murine species origin.
In an alternative embodiment, the heavy chain constant region sequence (CH) is shown in SEQ ID NO. 18 and the light chain constant region (CL) sequence is shown in SEQ ID NO. 19.
In other embodiments, the constant region sequence may have at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% homology to the above-described constant region (SEQ ID NO:18 or 19).
In alternative embodiments, the functional fragment is selected from any one of F (ab ') 2, fab', fab, fv, and scFv of the antibody.
The functional fragments of the above antibodies generally have the same binding specificity as the antibody from which they were derived. It will be readily appreciated by those skilled in the art from the disclosure herein that functional fragments of the above antibodies may be obtained by methods such as enzymatic digestion (including pepsin or papain) and/or by methods of chemical reduction cleavage of disulfide bonds. The above functional fragments are readily available to those skilled in the art based on the disclosure of the structure of the intact antibodies.
Functional fragments of the above antibodies may also be synthesized by recombinant genetic techniques also known to those skilled in the art or by, for example, automated peptide synthesizers such as those sold by Applied BioSystems and the like.
In another aspect, the application provides an antibody against methamphetamine comprising a heavy chain variable region as described above and a heavy chain constant region as described above; the light chain comprises the light chain variable region described above and the light chain constant region described above.
In an alternative embodiment, the amino acid sequence of the heavy chain is as shown in any one of SEQ ID NOs 26 to 29.
In an alternative embodiment, the amino acid sequence of the light chain is as shown in any one of SEQ ID NOs 30 to 31.
In another aspect, the application provides an antibody conjugate comprising an antibody or functional fragment thereof as described above.
In an alternative embodiment, the antibody or functional fragment thereof in the above antibody conjugate is labeled with a label.
In an alternative embodiment, the above-mentioned marker refers to a substance having a property such as luminescence, color development, radioactivity, etc., which can be directly observed by naked eyes or detected by an instrument, by which qualitative or quantitative detection of the corresponding target can be achieved.
In alternative embodiments, the labels include, but are not limited to, fluorescent dyes, enzymes, radioisotopes, chemiluminescent reagents, and nanoparticle-based labels.
In the actual use process, a person skilled in the art can select a suitable marker according to the detection conditions or actual needs, and no matter what marker is used, the marker belongs to the protection scope of the application.
In alternative embodiments, the fluorescent dyes include, but are not limited to, fluorescein-based dyes and derivatives thereof (including, but not limited to, fluorescein Isothiocyanate (FITC) hydroxy-light (FAM), tetrachlorolight (TET), and the like, or analogs thereof), rhodamine-based dyes and derivatives thereof (including, but not limited to, red Rhodamine (RBITC), tetramethyl rhodamine (TAMRA), rhodamine B (TRITC), and the like, or analogs thereof), cy-based dyes and derivatives thereof (including, but not limited to, cy2, cy3B, cy3.5, cy5, cy5.5, cy3, and the like, or analogs thereof), alexa-based dyes and derivatives thereof (including, but not limited to, alexa fluor350, 405, 430, 488, 532, 546, 555, 568, 594, 610, 33, 647, 680, 700, 750, and the like, or analogs thereof), and protein-based dyes and derivatives thereof (including, but not limited to, for example, phycoerythrin (PE), phycocyanin (PC), allophycocyanin (APC), polyazosin (chlorophyll), and the like).
In alternative embodiments, the enzymes include, but are not limited to, horseradish peroxidase, alkaline phosphatase, beta-galactosidase, glucose oxidase, carbonic anhydrase, acetylcholinesterase, and glucose 6-phosphate deoxygenase.
In alternative embodiments, the radioisotope includes, but is not limited to 212 Bi、 131 I、 111 In、 90 Y、 186 Re、 211 At、 125 I、 188 Re、 153 Sm、 213 Bi、 32 P、 94 mTc、 99 mTc、 203 Pb、 67 Ga、 68 Ga、 43 Sc、 47 Sc、 110 mIn、 97 Ru、 62 Cu、 64 Cu、 67 Cu、 68 Cu、 86 Y、 88 Y、 121 Sn、 161 Tb、 166 Ho、 105 Rh、 177 Lu、 172 Lu and 18 F。
in alternative embodiments, the chemiluminescent reagents include, but are not limited to, luminol and its derivatives, lucigenin, crustacean fluorescein and its derivatives, ruthenium bipyridine and its derivatives, acridinium esters and its derivatives, dioxane and its derivatives, lomustine and its derivatives, and peroxyoxalate and its derivatives.
In alternative embodiments, the nanoparticle-based labels include, but are not limited to, nanoparticles, colloids, organic nanoparticles, magnetic nanoparticles, quantum dot nanoparticles, and rare earth complex nanoparticles.
In alternative embodiments, the colloids include, but are not limited to, colloidal metals, disperse dyes, dye-labeled microspheres, and latex.
In alternative embodiments, the colloidal metals include, but are not limited to, colloidal gold, colloidal silver, and colloidal selenium.
In an alternative embodiment, the antibody or functional fragment thereof in the above antibody conjugate is coated onto a solid phase.
In alternative embodiments, the solid phase is selected from the group consisting of microspheres, plates, and membranes.
In alternative embodiments, the solid phase includes, but is not limited to, magnetic microspheres, plastic microparticles, microplates, glass, capillaries, nylon, and nitrocellulose membranes.
In an alternative embodiment, the solid phase is a nitrocellulose membrane.
In another aspect, the application provides a reagent or kit for detecting methamphetamine, the reagent or kit comprising an antibody or functional fragment thereof as described above or an antibody conjugate as described above.
In another aspect, the application provides the use of an antibody as described above or a functional fragment thereof, an antibody conjugate, or a reagent or kit as described above in the detection of methamphetamine.
In another aspect, the application provides a nucleic acid molecule encoding an antibody or functional fragment thereof as described above.
In another aspect, the application provides a vector comprising the nucleic acid molecule described above.
In another aspect, the application provides a cell comprising the vector described above.
In another aspect, the application provides a method of making an antibody or functional fragment thereof comprising: the cells as described above were cultured.
On the basis of the present application, which discloses the amino acid sequence of an antibody or a functional fragment thereof, it is easy for a person skilled in the art to prepare the antibody or the functional fragment thereof by genetic engineering techniques or other techniques (chemical synthesis, recombinant expression), for example, by separating and purifying the antibody or the functional fragment thereof from a culture product of recombinant cells capable of recombinantly expressing the antibody or the functional fragment thereof according to any one of the above, and on the basis of this, it is within the scope of the present application to prepare the antibody or the functional fragment thereof by any technique.
In order to make the objects, technical solutions and advantages of the embodiments of the present application more clear, the technical solutions of the embodiments of the present application will be clearly and completely described below. The specific conditions are not noted in the examples and are carried out according to conventional conditions or conditions recommended by the manufacturer. The reagents or apparatus used were conventional products commercially available without the manufacturer's attention.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of formulations or unit doses herein, some methods and materials are now described. Unless otherwise indicated, techniques employed or contemplated herein are standard methods. The materials, methods, and examples are illustrative only and not intended to be limiting.
Unless otherwise indicated, practice of the present application will employ conventional techniques of cell biology, molecular biology (including recombinant techniques), microbiology, biochemistry and immunology, which are within the ability of a person skilled in the art. This technique is well explained in the literature, as is the case for molecular cloning: laboratory Manual (Molecular Cloning: A Laboratory Manual), second edition (Sambrook et al, 1989); oligonucleotide Synthesis (Oligonucleotide Synthesis) (M.J.Gait et al, 1984); animal cell culture (Animal Cell Culture) (r.i. freshney, 1987); methods of enzymology (Methods in Enzymology) (Academic Press, inc.), experimental immunology handbook (Handbook of Experimental Immunology) (D.M.Weir and C.C.Blackwell, inc.), gene transfer vectors for mammalian cells (Gene Transfer Vectors for Mammalian Cells) (J.M.Miller and M.P.calos, inc., 1987), methods of contemporary molecular biology (Current Protocols in Molecular Biology) (F.M.Ausubel et al, inc., 1987), PCR: polymerase chain reaction (PCR: the Polymerase Chain Reaction, inc., 1994), and methods of contemporary immunology (Current Protocols in Immunology) (J.E.Coligan et al, 1991), each of which is expressly incorporated herein by reference.
The features and capabilities of the present application are described in further detail below in connection with the examples.
Example 1 preparation of Anti-MET-19G8 monoclonal antibody
Restriction enzymes, prime Star DNA polymerase in this example were purchased from Takara Corp. MagExtractor-RNA extraction kit was purchased from TOYOBO company. BD SMART TM RACE cDNA Amplification Kit kit was purchased from Takara. pMD-18T vector was purchased from Takara. Plasmid extraction kits were purchased from Tiangen. Primer synthesis and gene sequencing were accomplished by Invitrogen corporation.
1 construction of recombinant plasmid
(1) Antibody Gene production
mRNA is extracted from hybridoma cell strains secreting monoclonal antibodies against methamphetamine, a DNA product is obtained through an RT-PCR method, the product is inserted into a pMD-18T vector after an A adding reaction by rTaq DNA polymerase, the product is transformed into DH5 alpha competent cells, after colony growth, the Heavy Chain gene clone and the Light Chain gene clone are respectively taken, and 4 clones are sent to a gene sequencing company for sequencing.
(2) Sequence analysis of Anti-MET-19G8 antibody variable region Gene
The gene sequence obtained by sequencing is placed in a Kabat antibody database for analysis, and VNTI11.5 software is utilized for analysis to determine that the genes amplified by the heavy Chain primer pair and the Light Chain primer pair are correct, wherein in the gene fragment amplified by the Light Chain, the VL gene sequence is 324bp, and a leader peptide sequence of 57bp is arranged in front of the VL gene sequence; in the gene fragment amplified by the Heavy Chain primer pair, the VH gene sequence is 357bp, belongs to the VH1 gene family, and a 57bp leader peptide sequence is arranged in front of the VH gene family.
(3) Construction of recombinant antibody expression plasmids
pcDNA TM 3.4vector is a constructed eukaryotic expression vector of the recombinant antibody, and the expression vector is introduced into a HindIII, bamHI, ecoRI polyclonal enzyme cutting site, named pcDNA3.4A expression vector and is hereinafter abbreviated as 3.4A expression vector; according to the result of the antibody variable region gene sequencing in pMD-18T, VL and VH gene specific primers of the antibody are designed, hindIII, ecoRI restriction sites and protective bases are respectively arranged at two ends, and a 0.73kb Light Chain gene fragment and a 1.43kb Heavy Chain gene fragment are amplified by a PCR amplification method.
The Heavy Chain gene fragment and the Light Chain gene fragment are respectively cut by HindIII/EcoRI double enzyme, the 3.4A vector is cut by HindIII/EcoRI double enzyme, and the Heavy Chain gene fragment and the Light Chain gene fragment after the fragment and the vector are purified and recovered are respectively connected into the 3.4A expression vector to respectively obtain recombinant expression plasmids of the Heavy Chain gene fragment and the Light Chain gene fragment.
2 stable cell line selection
(1) Recombinant antibody expression plasmid transient transfection CHO cells, determination of expression plasmid activity
The plasmid was diluted to 40ug/100ul with ultrapure water and CHO cells were conditioned to 1.43X 10 7 100. Mu.L of plasmid was mixed with 700. Mu.L of cells in a centrifuge tube, transferred to an electrocuvette, electroblotted, sample counted on days 3, 5, 7, and harvested on day 7.
The coating solution (NaHCO 3 as the main ingredient) was diluted to 2ug/ml with MET-BSA (Handson, inc. HDS-A4008) at 4℃overnight at 100. Mu.L per well; the next day, washing with washing liquid for 2 times, and drying; blocking solution (20% BSA+80% PBS) was added, 120. Mu.L per well, 37℃for 1h, and the mixture was dried by shaking; adding diluted cell supernatant at 100. Mu.L/well, 37℃for 30min (1 h for part of supernatant); washing with washing liquid for 5 times, and drying; adding goat anti-mouse IgG-HRP, 100 mu L of each hole, and 30min at 37 ℃; washing with washing liquid for 5 times, and drying; adding a color development solution A (50 mu L/hole, containing citric acid, sodium acetate, acetanilide and carbamide peroxide), and adding a color development solution B (50 mu L/hole, containing citric acid, EDTA, 2Na+TMB and concentrated HCL) for 10min; adding stop solution (50. Mu.L/well, EDTA. 2Na+ concentrated H) 2 SO 4 ) The method comprises the steps of carrying out a first treatment on the surface of the OD was read on the microplate reader at 450nm (reference 630 nm). The results showed that the reaction OD after 1000-fold dilution of the cell supernatant was still greater than 1.0, and that the reaction OD without cell supernatant wells was less than 0.1, indicating that antibodies produced after transient transformation of the plasmid were active on MET-BSA.
The reactivity of the cell supernatant with BSA was examined by the same method as described above, and the result showed that the cell supernatant was diluted 1000 times and the OD was less than 0.1, and that the cell supernatant was not added and the OD was less than 0.1, indicating that the antibody produced after transient transformation of the plasmid was inactive against BSA, further demonstrating that the cell supernatant was active against MET.
(2) Linearization of recombinant antibody expression plasmids
The following reagents were prepared: buffer 50 mu L, DNA mu g/tube, puv I enzyme 10 mu L, sterile water to 500 mu L, water bath at 37 ℃ for enzyme digestion overnight; firstly, extracting with equal volume of phenol/chloroform/isoamyl alcohol (lower layer) 25:24:1, and then sequentially extracting with chloroform (water phase); precipitating 0.1 times volume (water phase) of 3M sodium acetate and 2 times volume of ethanol on ice, rinsing the precipitate with 70% ethanol, removing organic solvent, completely volatilizing ethanol, re-thawing with appropriate amount of sterilized water, and measuring concentration.
(3) Stable transfection of recombinant antibody expression plasmid and pressure screening of stable cell strain
The plasmid was diluted to 40ug/100ul with ultrapure water and CHO cells were conditioned to 1.43X 10 7 Placing cells/ml in a centrifuge tube, mixing 100 μl of plasmid with 700 μl of cells, transferring into an electrorotor, electrorotating, and counting the next day; 25umol/L MSX 96-well pressure culture for about 25 days.
Observing the clone holes with the cells under a microscope, and recording the confluency; taking culture supernatant, and carrying out sample feeding detection; selecting cell strains with high antibody concentration and relative concentration, turning 24 holes, and turning 6 holes about 3 days; seed preservation and batch culture are carried out after 3 days, and cell density is regulated to be 0.5x10 6 Batch culture was performed with cells/ml,2.2ml, and cell density was 0.3X10 6 Performing seed preservation by using cells/ml and 2 ml; and (3) carrying out sample feeding detection on the culture supernatant of the 6-hole batch culture for 7 days, and selecting cell strains with smaller antibody concentration and smaller cell diameter to transfer TPP for seed preservation and passage.
3 recombinant antibody production
(1) Cell expansion culture
After cell recovery, the cells were first cultured in 125ml shake flasks with an inoculation volume of 30ml and a medium of 100% dynamis and placed in a shaker at a speed of 120r/min at 37℃and with 8% carbon dioxide. Culturing for 72h, inoculating and expanding culture at 50 ten thousand cells/ml inoculating density, and calculating the expanding culture volume according to production requirements, wherein the culture medium is 100% Dynamis culture medium. After that, the culture was spread every 72 hours. When the cell quantity meets the production requirement, the inoculation density is strictly controlled to be about 50 ten thousand cells/ml for production.
(2) Shake flask production and purification
Shake flask parameters: the rotating speed is 120r/min, the temperature is 37 ℃, and the carbon dioxide is 8%. Feeding: feeding was started every day until 72h of culture in shake flasks, hyCloneTM Cell BoostTM Feed a fed-batch was 3% of the initial culture volume every day, feed 7b fed-batch was one thousandth of the initial culture volume every day, and fed-batch was continued until day 12 (day 12 Feed). Glucose was fed at 3g/L on day six. Samples were collected on day 13. Affinity purification was performed using a proteona affinity column. 3 μg of purified antibody was subjected to reducing SDS-PAGE, and the electrophoretogram shows two bands after reducing SDS-PAGE, 1 Mr at 50KD and the other Mr at 28KD.
Example 2 affinity and Activity optimization
The Anti-MET-19G8 monoclonal antibody obtained in example 1 had an ability to bind methamphetamine, but was not sufficiently excellent in affinity and antibody activity, and thus, the applicant had performed directed mutation on the light chain CDRs and the heavy chain CDRs of the antibody. The method comprises the steps of performing structural simulation of an antibody variable region, structural simulation of an antigen-antibody variable region acting complex, analysis of key amino acids of an antibody and mutation design by using a computer, designing and synthesizing a two-way primer covering a mutation site according to a mutation scheme, synthesizing primers at two ends of target DNA, performing high-fidelity PCR reaction, cloning a PCR product to a vector, and preparing the mutant antibody according to the method described in the example 1. Monoclonal antibodies with remarkably improved affinity and antibody activity are obtained through screening and are named as: anti-MET-19G8mut1 to Anti-MET-19G8mut5. The amino acid sequences of the respective monoclonal antibodies are shown in the following table:
TABLE 1 antibody sequences
Example 3 detection of Performance of antibodies
1 affinity assay
Using the AMC sensor, the purified antibodies were diluted to 10ug/ml with PBST, and MET-BSA (Handson, cat. HDS-A4008) was gradient diluted with PBST:
the operation flow is as follows: equilibration for 60s in buffer 1 (PBST), antibody 300s in antibody solution, incubation for 180s in buffer 2 (PBST), binding for 420s in antigen solution, dissociation for 1200s in buffer 2, sensor regeneration with 10mM pH 1.69GLY solution and buffer 3 (PBST), output data. (KD represents equilibrium dissociation constant, i.e., affinity; kon represents binding rate; kdis represents dissociation rate. PBST major component Na2 HPO4+NaCl+TW-20).
Table 2 affinity data
Sample name KD(M) kon(1/Ms) kdis(1/s)
Control 4.83E-07 3.19E+04 1.54E-02
Anti-MET-19G8mut1 2.02E-08 1.15E+05 2.32E-03
Anti-MET-19G8mut2 2.62E-08 1.66E+05 4.35E-03
Anti-MET-19G8mut3 5.12E-08 1.75E+05 8.96E-03
Anti-MET-19G8mut4 4.12E-08 2.25E+05 9.27E-03
Anti-MET-19G8mut5 2.08E-08 1.22E+05 2.54E-03
2 Activity assay
The coating solution (NaHCO 3 as the main ingredient) was diluted to 2ug/ml with MET-BSA (Handson, inc. HDS-A4008) at 4℃overnight at 100. Mu.L per well; the next day, washing with washing liquid for 2 times, and drying; blocking solution (20% BSA+80% PBS) was added, 120. Mu.l per well, 37℃for 1h, and the mixture was dried by pipetting; adding the diluted monoclonal antibody into the mixture at the temperature of 37 ℃ for 30-60 min at the concentration of 100 mu l/hole; washing with washing liquid for 5 times, and drying; adding goat anti-mouse IgG-HRP, 100 μl per well, 37deg.C, 30min; washing with washing solution (PBS) for 5 times, and drying; adding a color development solution A (50. Mu.l/hole, containing 2.1g/L citric acid, 12.25g/L citric acid, 0.07g/L acetanilide and 0.5g/L carbamide peroxide), and adding a color development solution B (50. Mu.l/hole, containing 1.05g/L citric acid, 0.186 g/LEDTA.2Na, 0.45g/L TMB and 0.2ml/L concentrated HCl) for 10min; adding stop solution (50. Mu.l/well, 0.75 g/EDTA.2Na and 10.2ml/L of concentrated H) 2 SO 4 ) The method comprises the steps of carrying out a first treatment on the surface of the OD was read on the microplate reader at 450nm (reference 630 nm). The results are shown in the following table.
TABLE 3 Activity data
3 stability assessment
Placing the antibody at 4 ℃ (refrigerator), 80 ℃ (refrigerator) and 37 ℃ (incubator) for 21 days, taking 7 days, 14 days and 21 days samples for state observation, and detecting the activity of the 21 days samples, wherein the result shows that no obvious protein state change is seen for the antibody placed for 21 days under three examination conditions, and the activity is not in a descending trend along with the increase of the examination temperature, thus indicating that the antibody is stable. Table 4 below shows the results of the detection of OD after 21 days of antibody examination.
Table 4 stability data
Sample concentration (ng/ml) 31.25 7.813 0
4 ℃,21 days sample 1.333 0.387 0.043
Sample at-80℃for 21 days 1.376 0.401 0.032
37 ℃ and 21 days of sample 1.312 0.357 0.037
The above description is only of the preferred embodiments of the present application and is not intended to limit the present application, but various modifications and variations can be made to the present application by those skilled in the art. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present application should be included in the protection scope of the present application.
The partial amino acid sequence related to the application is as follows:
sequence numbering Sequence fragments
SEQ ID NO:1 DYYMY
SEQ ID NO:2 YVDPYNGITSYNQKFKG
SEQ ID NO:3 AFGKGVYYF
SEQ ID NO:4 SASSSVPSSYLY
SEQ ID NO:5 STSNLAS
SEQ ID NO:6 HQWSSYP
SEQ ID NO:15 YVDPYNGLTSYNQKFKG
SEQUENCE LISTING
<110> Dongguan City, pengzhi biotechnology Co., ltd
<120> anti-methamphetamine antibodies, reagents and kits for detecting methamphetamine
<130> P2022051CN01
<160> 31
<170> PatentIn version 3.3
<210> 1
<211> 5
<212> PRT
<213> Artificial
<220>
<223> Artificial sequence
<400> 1
Asp Tyr Tyr Met Tyr
1 5
<210> 2
<211> 17
<212> PRT
<213> Artificial
<220>
<223> Artificial sequence
<400> 2
Tyr Val Asp Pro Tyr Asn Gly Ile Thr Ser Tyr Asn Gln Lys Phe Lys
1 5 10 15
Gly
<210> 3
<211> 9
<212> PRT
<213> Artificial
<220>
<223> Artificial sequence
<400> 3
Ala Phe Gly Lys Gly Val Tyr Tyr Phe
1 5
<210> 4
<211> 12
<212> PRT
<213> Artificial
<220>
<223> Artificial sequence
<400> 4
Ser Ala Ser Ser Ser Val Pro Ser Ser Tyr Leu Tyr
1 5 10
<210> 5
<211> 7
<212> PRT
<213> Artificial
<220>
<223> Artificial sequence
<400> 5
Ser Thr Ser Asn Leu Ala Ser
1 5
<210> 6
<211> 7
<212> PRT
<213> Artificial
<220>
<223> Artificial sequence
<400> 6
His Gln Trp Ser Ser Tyr Pro
1 5
<210> 7
<211> 30
<212> PRT
<213> Artificial
<220>
<223> Artificial sequence
<400> 7
Glu Ile Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr
20 25 30
<210> 8
<211> 14
<212> PRT
<213> Artificial
<220>
<223> Artificial sequence
<400> 8
Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Tyr Ile Gly
1 5 10
<210> 9
<211> 31
<212> PRT
<213> Artificial
<220>
<223> Artificial sequence
<400> 9
Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Phe Met His
1 5 10 15
Leu Asn Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala
20 25 30
<210> 10
<211> 13
<212> PRT
<213> Artificial
<220>
<223> Artificial sequence
<400> 10
Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser
1 5 10
<210> 11
<211> 23
<212> PRT
<213> Artificial
<220>
<223> Artificial sequence
<400> 11
Gln Ile Val Leu Thr Gln Ser Pro Ala Phe Met Ser Ala Ser Pro Gly
1 5 10 15
Glu Lys Val Thr Leu Thr Cys
20
<210> 12
<211> 15
<212> PRT
<213> Artificial
<220>
<223> Artificial sequence
<400> 12
Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Leu Trp Ile Tyr
1 5 10 15
<210> 13
<211> 32
<212> PRT
<213> Artificial
<220>
<223> Artificial sequence
<400> 13
Gly Val Pro Thr Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser
1 5 10 15
Leu Thr Ile Ser Ser Met Glu Ala Glu Asp Ala Ala Ser Tyr Phe Cys
20 25 30
<210> 14
<211> 12
<212> PRT
<213> Artificial
<220>
<223> Artificial sequence
<400> 14
Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys
1 5 10
<210> 15
<211> 17
<212> PRT
<213> Artificial
<220>
<223> Artificial sequence
<400> 15
Tyr Val Asp Pro Tyr Asn Gly Leu Thr Ser Tyr Asn Gln Lys Phe Lys
1 5 10 15
Gly
<210> 16
<211> 31
<212> PRT
<213> Artificial
<220>
<223> Artificial sequence
<400> 16
Lys Ala Thr Ile Thr Val Asp Lys Ser Ser Ser Thr Ala Phe Met His
1 5 10 15
Leu Asn Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala
20 25 30
<210> 17
<211> 23
<212> PRT
<213> Artificial
<220>
<223> Artificial sequence
<400> 17
Gln Ile Val Leu Thr Gln Ser Pro Ala Phe Met Ser Ala Ser Pro Gly
1 5 10 15
Glu Lys Val Thr Ile Thr Cys
20
<210> 18
<211> 329
<212> PRT
<213> Artificial
<220>
<223> Artificial sequence
<400> 18
Ala Lys Thr Thr Ala Pro Ser Val Tyr Pro Leu Ala Pro Val Cys Gly
1 5 10 15
Asp Thr Thr Gly Ser Ser Val Thr Leu Gly Cys Leu Val Lys Gly Tyr
20 25 30
Phe Pro Glu Pro Val Thr Leu Thr Trp Asn Ser Gly Ser Leu Ser Ser
35 40 45
Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Asp Leu Tyr Thr Leu
50 55 60
Ser Ser Ser Val Thr Val Thr Ser Ser Thr Trp Pro Ser Gln Ser Ile
65 70 75 80
Thr Cys Asn Val Ala His Pro Ala Ser Ser Thr Lys Val Asp Lys Lys
85 90 95
Ile Glu Pro Arg Gly Pro Thr Ile Lys Pro Cys Pro Pro Cys Lys Cys
100 105 110
Pro Ala Pro Asn Leu Leu Gly Gly Pro Ser Val Phe Ile Phe Pro Pro
115 120 125
Lys Ile Lys Asp Val Leu Met Ile Ser Leu Ser Pro Ile Val Thr Cys
130 135 140
Val Val Val Asp Val Ser Glu Asp Asp Pro Asp Val Gln Ile Ser Trp
145 150 155 160
Phe Val Asn Asn Val Glu Val His Thr Ala Gln Thr Gln Thr His Arg
165 170 175
Glu Asp Tyr Asn Ser Thr Leu Arg Val Val Ser Ala Leu Pro Ile Gln
180 185 190
His Gln Asp Trp Met Ser Gly Lys Glu Phe Lys Cys Lys Val Asn Asn
195 200 205
Lys Asp Leu Pro Ala Pro Ile Glu Arg Thr Ile Ser Lys Pro Lys Gly
210 215 220
Ser Val Arg Ala Pro Gln Val Tyr Val Leu Pro Pro Pro Glu Glu Glu
225 230 235 240
Met Thr Lys Lys Gln Val Thr Leu Thr Cys Met Val Thr Asp Phe Met
245 250 255
Pro Glu Asp Ile Tyr Val Glu Trp Thr Asn Asn Gly Lys Thr Glu Leu
260 265 270
Asn Tyr Lys Asn Thr Glu Pro Val Leu Asp Ser Asp Gly Ser Tyr Phe
275 280 285
Met Tyr Ser Lys Leu Arg Val Glu Lys Lys Asn Trp Val Glu Arg Asn
290 295 300
Ser Tyr Ser Cys Ser Val Val His Glu Gly Leu His Asn His His Thr
305 310 315 320
Thr Lys Ser Phe Ser Arg Thr Pro Gly
325
<210> 19
<211> 107
<212> PRT
<213> Artificial
<220>
<223> Artificial sequence
<400> 19
Arg Ala Asp Ala Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu
1 5 10 15
Gln Leu Thr Ser Gly Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe
20 25 30
Tyr Pro Lys Asp Ile Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg
35 40 45
Gln Asn Gly Val Leu Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser
50 55 60
Thr Tyr Ser Met Ser Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu
65 70 75 80
Arg His Asn Ser Tyr Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser
85 90 95
Pro Ile Val Lys Ser Phe Asn Arg Asn Glu Cys
100 105
<210> 20
<211> 119
<212> PRT
<213> Artificial
<220>
<223> Artificial sequence
<400> 20
Glu Ile Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Asp Tyr
20 25 30
Tyr Met Tyr Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Tyr Ile
35 40 45
Gly Tyr Val Asp Pro Tyr Asn Gly Ile Thr Ser Tyr Asn Gln Lys Phe
50 55 60
Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Phe
65 70 75 80
Met His Leu Asn Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
85 90 95
Ala Ala Phe Gly Lys Gly Val Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly
100 105 110
Thr Thr Leu Thr Val Ser Ser
115
<210> 21
<211> 119
<212> PRT
<213> Artificial
<220>
<223> Artificial sequence
<400> 21
Glu Ile Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Asp Tyr
20 25 30
Tyr Met Tyr Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Tyr Ile
35 40 45
Gly Tyr Val Asp Pro Tyr Asn Gly Ile Thr Ser Tyr Asn Gln Lys Phe
50 55 60
Lys Gly Lys Ala Thr Ile Thr Val Asp Lys Ser Ser Ser Thr Ala Phe
65 70 75 80
Met His Leu Asn Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
85 90 95
Ala Ala Phe Gly Lys Gly Val Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly
100 105 110
Thr Thr Leu Thr Val Ser Ser
115
<210> 22
<211> 119
<212> PRT
<213> Artificial
<220>
<223> Artificial sequence
<400> 22
Glu Ile Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Asp Tyr
20 25 30
Tyr Met Tyr Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Tyr Ile
35 40 45
Gly Tyr Val Asp Pro Tyr Asn Gly Leu Thr Ser Tyr Asn Gln Lys Phe
50 55 60
Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Phe
65 70 75 80
Met His Leu Asn Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
85 90 95
Ala Ala Phe Gly Lys Gly Val Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly
100 105 110
Thr Thr Leu Thr Val Ser Ser
115
<210> 23
<211> 119
<212> PRT
<213> Artificial
<220>
<223> Artificial sequence
<400> 23
Glu Ile Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Asp Tyr
20 25 30
Tyr Met Tyr Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Tyr Ile
35 40 45
Gly Tyr Val Asp Pro Tyr Asn Gly Leu Thr Ser Tyr Asn Gln Lys Phe
50 55 60
Lys Gly Lys Ala Thr Ile Thr Val Asp Lys Ser Ser Ser Thr Ala Phe
65 70 75 80
Met His Leu Asn Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
85 90 95
Ala Ala Phe Gly Lys Gly Val Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly
100 105 110
Thr Thr Leu Thr Val Ser Ser
115
<210> 24
<211> 108
<212> PRT
<213> Artificial
<220>
<223> Artificial sequence
<400> 24
Gln Ile Val Leu Thr Gln Ser Pro Ala Phe Met Ser Ala Ser Pro Gly
1 5 10 15
Glu Lys Val Thr Leu Thr Cys Ser Ala Ser Ser Ser Val Pro Ser Ser
20 25 30
Tyr Leu Tyr Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Leu Trp
35 40 45
Ile Tyr Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Thr Arg Phe Ser
50 55 60
Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu
65 70 75 80
Ala Glu Asp Ala Ala Ser Tyr Phe Cys His Gln Trp Ser Ser Tyr Pro
85 90 95
Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys
100 105
<210> 25
<211> 108
<212> PRT
<213> Artificial
<220>
<223> Artificial sequence
<400> 25
Gln Ile Val Leu Thr Gln Ser Pro Ala Phe Met Ser Ala Ser Pro Gly
1 5 10 15
Glu Lys Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Val Pro Ser Ser
20 25 30
Tyr Leu Tyr Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Leu Trp
35 40 45
Ile Tyr Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Thr Arg Phe Ser
50 55 60
Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu
65 70 75 80
Ala Glu Asp Ala Ala Ser Tyr Phe Cys His Gln Trp Ser Ser Tyr Pro
85 90 95
Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys
100 105
<210> 26
<211> 448
<212> PRT
<213> Artificial
<220>
<223> Artificial sequence
<400> 26
Glu Ile Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Asp Tyr
20 25 30
Tyr Met Tyr Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Tyr Ile
35 40 45
Gly Tyr Val Asp Pro Tyr Asn Gly Ile Thr Ser Tyr Asn Gln Lys Phe
50 55 60
Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Phe
65 70 75 80
Met His Leu Asn Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
85 90 95
Ala Ala Phe Gly Lys Gly Val Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly
100 105 110
Thr Thr Leu Thr Val Ser Ser Ala Lys Thr Thr Ala Pro Ser Val Tyr
115 120 125
Pro Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Val Thr Leu
130 135 140
Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu Thr Trp
145 150 155 160
Asn Ser Gly Ser Leu Ser Ser Gly Val His Thr Phe Pro Ala Val Leu
165 170 175
Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Thr Ser Ser
180 185 190
Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro Ala Ser
195 200 205
Ser Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr Ile Lys
210 215 220
Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly Gly Pro
225 230 235 240
Ser Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met Ile Ser
245 250 255
Leu Ser Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu Asp Asp
260 265 270
Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His Thr
275 280 285
Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu Arg Val
290 295 300
Val Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys Glu
305 310 315 320
Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile Glu Arg
325 330 335
Thr Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val Tyr Val
340 345 350
Leu Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr Leu Thr
355 360 365
Cys Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu Trp Thr
370 375 380
Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro Val Leu
385 390 395 400
Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val Glu Lys
405 410 415
Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val His Glu
420 425 430
Gly Leu His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr Pro Gly
435 440 445
<210> 27
<211> 448
<212> PRT
<213> Artificial
<220>
<223> Artificial sequence
<400> 27
Glu Ile Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Asp Tyr
20 25 30
Tyr Met Tyr Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Tyr Ile
35 40 45
Gly Tyr Val Asp Pro Tyr Asn Gly Ile Thr Ser Tyr Asn Gln Lys Phe
50 55 60
Lys Gly Lys Ala Thr Ile Thr Val Asp Lys Ser Ser Ser Thr Ala Phe
65 70 75 80
Met His Leu Asn Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
85 90 95
Ala Ala Phe Gly Lys Gly Val Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly
100 105 110
Thr Thr Leu Thr Val Ser Ser Ala Lys Thr Thr Ala Pro Ser Val Tyr
115 120 125
Pro Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Val Thr Leu
130 135 140
Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu Thr Trp
145 150 155 160
Asn Ser Gly Ser Leu Ser Ser Gly Val His Thr Phe Pro Ala Val Leu
165 170 175
Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Thr Ser Ser
180 185 190
Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro Ala Ser
195 200 205
Ser Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr Ile Lys
210 215 220
Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly Gly Pro
225 230 235 240
Ser Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met Ile Ser
245 250 255
Leu Ser Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu Asp Asp
260 265 270
Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His Thr
275 280 285
Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu Arg Val
290 295 300
Val Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys Glu
305 310 315 320
Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile Glu Arg
325 330 335
Thr Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val Tyr Val
340 345 350
Leu Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr Leu Thr
355 360 365
Cys Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu Trp Thr
370 375 380
Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro Val Leu
385 390 395 400
Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val Glu Lys
405 410 415
Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val His Glu
420 425 430
Gly Leu His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr Pro Gly
435 440 445
<210> 28
<211> 448
<212> PRT
<213> Artificial
<220>
<223> Artificial sequence
<400> 28
Glu Ile Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Asp Tyr
20 25 30
Tyr Met Tyr Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Tyr Ile
35 40 45
Gly Tyr Val Asp Pro Tyr Asn Gly Leu Thr Ser Tyr Asn Gln Lys Phe
50 55 60
Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Phe
65 70 75 80
Met His Leu Asn Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
85 90 95
Ala Ala Phe Gly Lys Gly Val Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly
100 105 110
Thr Thr Leu Thr Val Ser Ser Ala Lys Thr Thr Ala Pro Ser Val Tyr
115 120 125
Pro Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Val Thr Leu
130 135 140
Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu Thr Trp
145 150 155 160
Asn Ser Gly Ser Leu Ser Ser Gly Val His Thr Phe Pro Ala Val Leu
165 170 175
Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Thr Ser Ser
180 185 190
Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro Ala Ser
195 200 205
Ser Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr Ile Lys
210 215 220
Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly Gly Pro
225 230 235 240
Ser Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met Ile Ser
245 250 255
Leu Ser Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu Asp Asp
260 265 270
Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His Thr
275 280 285
Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu Arg Val
290 295 300
Val Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys Glu
305 310 315 320
Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile Glu Arg
325 330 335
Thr Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val Tyr Val
340 345 350
Leu Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr Leu Thr
355 360 365
Cys Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu Trp Thr
370 375 380
Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro Val Leu
385 390 395 400
Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val Glu Lys
405 410 415
Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val His Glu
420 425 430
Gly Leu His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr Pro Gly
435 440 445
<210> 29
<211> 448
<212> PRT
<213> Artificial
<220>
<223> Artificial sequence
<400> 29
Glu Ile Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Asp Tyr
20 25 30
Tyr Met Tyr Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Tyr Ile
35 40 45
Gly Tyr Val Asp Pro Tyr Asn Gly Leu Thr Ser Tyr Asn Gln Lys Phe
50 55 60
Lys Gly Lys Ala Thr Ile Thr Val Asp Lys Ser Ser Ser Thr Ala Phe
65 70 75 80
Met His Leu Asn Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
85 90 95
Ala Ala Phe Gly Lys Gly Val Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly
100 105 110
Thr Thr Leu Thr Val Ser Ser Ala Lys Thr Thr Ala Pro Ser Val Tyr
115 120 125
Pro Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Val Thr Leu
130 135 140
Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu Thr Trp
145 150 155 160
Asn Ser Gly Ser Leu Ser Ser Gly Val His Thr Phe Pro Ala Val Leu
165 170 175
Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Thr Ser Ser
180 185 190
Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro Ala Ser
195 200 205
Ser Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr Ile Lys
210 215 220
Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly Gly Pro
225 230 235 240
Ser Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met Ile Ser
245 250 255
Leu Ser Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu Asp Asp
260 265 270
Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His Thr
275 280 285
Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu Arg Val
290 295 300
Val Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys Glu
305 310 315 320
Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile Glu Arg
325 330 335
Thr Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val Tyr Val
340 345 350
Leu Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr Leu Thr
355 360 365
Cys Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu Trp Thr
370 375 380
Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro Val Leu
385 390 395 400
Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val Glu Lys
405 410 415
Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val His Glu
420 425 430
Gly Leu His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr Pro Gly
435 440 445
<210> 30
<211> 215
<212> PRT
<213> Artificial
<220>
<223> Artificial sequence
<400> 30
Gln Ile Val Leu Thr Gln Ser Pro Ala Phe Met Ser Ala Ser Pro Gly
1 5 10 15
Glu Lys Val Thr Leu Thr Cys Ser Ala Ser Ser Ser Val Pro Ser Ser
20 25 30
Tyr Leu Tyr Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Leu Trp
35 40 45
Ile Tyr Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Thr Arg Phe Ser
50 55 60
Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu
65 70 75 80
Ala Glu Asp Ala Ala Ser Tyr Phe Cys His Gln Trp Ser Ser Tyr Pro
85 90 95
Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys Arg Ala Asp Ala
100 105 110
Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser
115 120 125
Gly Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp
130 135 140
Ile Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val
145 150 155 160
Leu Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met
165 170 175
Ser Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser
180 185 190
Tyr Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys
195 200 205
Ser Phe Asn Arg Asn Glu Cys
210 215
<210> 31
<211> 215
<212> PRT
<213> Artificial
<220>
<223> Artificial sequence
<400> 31
Gln Ile Val Leu Thr Gln Ser Pro Ala Phe Met Ser Ala Ser Pro Gly
1 5 10 15
Glu Lys Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Val Pro Ser Ser
20 25 30
Tyr Leu Tyr Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Leu Trp
35 40 45
Ile Tyr Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Thr Arg Phe Ser
50 55 60
Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu
65 70 75 80
Ala Glu Asp Ala Ala Ser Tyr Phe Cys His Gln Trp Ser Ser Tyr Pro
85 90 95
Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys Arg Ala Asp Ala
100 105 110
Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser
115 120 125
Gly Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp
130 135 140
Ile Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val
145 150 155 160
Leu Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met
165 170 175
Ser Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser
180 185 190
Tyr Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys
195 200 205
Ser Phe Asn Arg Asn Glu Cys
210 215

Claims (12)

1. An anti-methamphetamine antibody or a functional fragment thereof, wherein the antibody or the functional fragment thereof comprises HCDR1 with an amino acid sequence shown as SEQ ID NO. 1, HCDR2 with an amino acid sequence shown as SEQ ID NO. 2 or 15, HCDR3 with an amino acid sequence shown as SEQ ID NO. 3, and LCDR1 with an amino acid sequence shown as SEQ ID NO. 4, LCDR2 with an amino acid sequence shown as SEQ ID NO. 5, and LCDR3 with an amino acid sequence shown as SEQ ID NO. 6.
2. The antibody or functional fragment thereof according to claim 1, wherein the antibody or functional fragment thereof further comprises HFR1, HFR2, HFR3, HFR4 having the amino acid sequences shown in SEQ ID No. 7 to SEQ ID No. 10 and LFR1, LFR2, LFR3 and LFR4 having the amino acid sequences shown in SEQ ID No. 11 to SEQ ID No. 14, or an amino acid sequence having at least 80% homology with each of said sequences;
alternatively, the antibody or functional fragment thereof is produced with a KD of 4.83×10 or less -7 The affinity of M binds methamphetamine;
optionally, the amino acid sequence of HFR3 of the antibody or functional fragment thereof is shown in SEQ ID NO. 16;
alternatively, the amino acid sequence of LFR1 of said antibody or functional fragment thereof is shown as SEQ ID NO. 17.
3. An anti-methamphetamine antibody or a functional fragment thereof, wherein the antibody or functional fragment thereof comprises a heavy chain variable region comprising the sequence structure of HFR1-HCDR 2-HFR3-HCDR3-HFR4 and/or a light chain variable region comprising the sequence structure of LFR1-LCDR 2-LFR3-LCDR3-LFR4, wherein the amino acid sequence of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3 is the amino acid sequence of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3, HFR1, HFR2, HFR4, LFR1, LFR2, LFR3, LFR4 is the amino acid sequence of HFR1, HFR2, HFR3, LCDR3, LFR4 of claim 1, HFR 2;
alternatively, the heavy chain variable region amino acid sequence is as shown in any one of SEQ ID NOs 20 to 23;
alternatively, the light chain variable region amino acid sequence is set forth in any one of SEQ ID NOs 24 to 25.
4. The antibody or functional fragment thereof according to any one of claims 1 to 3, wherein the antibody or functional fragment thereof further comprises a constant region;
optionally, the constant region comprises a heavy chain constant region and/or a light chain constant region;
alternatively, the heavy chain constant region is selected from the group consisting of the heavy chain constant region of IgG1, igG2, igG3, igG4, igA, igM, igE or IgD; the light chain constant region is selected from a kappa-type or lambda-type light chain constant region;
alternatively, the constant region is of bovine, equine, porcine, ovine, caprine, rat, mouse, canine, feline, rabbit, donkey, deer, mink, chicken, duck, goose, or human origin;
alternatively, the constant region is of mouse species origin;
alternatively, the heavy chain constant region sequence is as shown in SEQ ID NO. 18 or has at least 80% homology thereto;
alternatively, the light chain constant region sequence is as shown in SEQ ID NO. 19 or has at least 80% homology thereto.
5. The antibody or functional fragment thereof according to any one of claims 1 to 4, wherein the functional fragment is selected from any one of F (ab ') 2, fab', fab, fv and scFv of the antibody.
6. An anti-methamphetamine antibody comprising a heavy chain and/or a light chain, wherein the heavy chain comprises the heavy chain variable region of claim 3 and the heavy chain constant region of claim 4; the light chain comprises the light chain variable region of claim 3 and the light chain constant region of claim 4;
alternatively, the heavy chain has an amino acid sequence as set forth in any one of SEQ ID NOs 26 to 29;
alternatively, the amino acid sequence of the light chain is as shown in any one of SEQ ID NOs 30 to 31.
7. An antibody conjugate comprising the antibody or functional fragment thereof of any one of claims 1 to 6;
optionally, the antibody or functional fragment thereof is labeled with a label;
optionally, the label is selected from the group consisting of fluorescent dyes, enzymes, radioisotopes, chemiluminescent reagents, and nanoparticle-based labels;
optionally, the fluorescent dye is selected from fluorescein dye and its derivative, rhodamine dye and its derivative, cy series dye and its derivative, alexa series dye and its derivative, and protein dye and its derivative;
alternatively, the enzyme is selected from horseradish peroxidase, alkaline phosphatase, beta-galactosidase, glucose oxidase, carbonic anhydrase, acetylcholinesterase, and glucose-6-phosphate deoxygenase;
optionally, the radioisotope is selected from 212Bi, 131I, 111In, 90Y, 186Re, 211At, 125I, 188Re, 153Sm, 213Bi, 32P, 94mTc, 99mTc, 203Pb, 67Ga, 68Ga, 43Sc, 47Sc, 110 msin, 97Ru, 62Cu, 64Cu, 67Cu, 68Cu, 86Y, 88Y, 121Sn, 161Tb, 166Ho, 105Rh, 177Lu, 172Lu and 18F;
optionally, the chemiluminescent reagent is selected from luminol and its derivatives, lucigenin, crustacean fluorescein and its derivatives, ruthenium bipyridine and its derivatives, acridinium esters and its derivatives, dioxane and its derivatives, clorine and its derivatives, and peroxyoxalate and its derivatives;
optionally, the nanoparticle-based label is selected from the group consisting of nanoparticles, colloids, organic nanoparticles, magnetic nanoparticles, quantum dot nanoparticles, and rare earth complex nanoparticles;
optionally, the colloid is selected from the group consisting of colloidal metals, disperse dyes, dye-labeled microspheres, and latex;
optionally, the colloidal metal is selected from the group consisting of colloidal gold, colloidal silver, and colloidal selenium;
optionally, the antibody or functional fragment thereof is coated to a solid phase;
alternatively, the solid phase is selected from the group consisting of microspheres, plates, and membranes;
alternatively, the solid phase is selected from the group consisting of magnetic microspheres, plastic microparticles, microplates, glass, capillaries, nylon and nitrocellulose membranes.
8. A reagent or kit for detecting methamphetamine, comprising an antibody or functional fragment thereof according to any one of claims 1 to 6 or an antibody conjugate according to claim 7.
9. A nucleic acid encoding the antibody or functional fragment thereof of any one of claims 1 to 6.
10. A vector comprising the nucleic acid of claim 10.
11. A cell comprising the nucleic acid of claim 10 or the vector of claim 11.
12. A method of preparing an antibody or functional fragment thereof according to any one of claims 1 to 6, comprising: culturing the cell of claim 12.
CN202210509727.7A 2022-05-11 2022-05-11 Anti-methamphetamine antibodies, reagents and kits for detecting methamphetamine Pending CN117088982A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210509727.7A CN117088982A (en) 2022-05-11 2022-05-11 Anti-methamphetamine antibodies, reagents and kits for detecting methamphetamine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202210509727.7A CN117088982A (en) 2022-05-11 2022-05-11 Anti-methamphetamine antibodies, reagents and kits for detecting methamphetamine

Publications (1)

Publication Number Publication Date
CN117088982A true CN117088982A (en) 2023-11-21

Family

ID=88782139

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202210509727.7A Pending CN117088982A (en) 2022-05-11 2022-05-11 Anti-methamphetamine antibodies, reagents and kits for detecting methamphetamine

Country Status (1)

Country Link
CN (1) CN117088982A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117088983A (en) * 2022-05-11 2023-11-21 东莞市朋志生物科技有限公司 Anti-amphetamine antibodies, reagents and kits for detecting amphetamine

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0311383A2 (en) * 1987-10-09 1989-04-12 Ube Industries, Ltd. Monoclonal antibody to methamphetamine, preparation of the same, assay method and assay kit of methamphetamine
CN1179469A (en) * 1996-10-11 1998-04-22 财团法人生物技术开发中心 Monoclonal antibody of p-methyl benzedrine with specificity, hybridoma producing same and kit containing monoclonal antibody and its use
CN1410770A (en) * 2002-11-22 2003-04-16 上海凯创生物技术有限公司 Reagent box for fast detecting methyl amphetamine and its preparation process
US20080125579A1 (en) * 2006-06-15 2008-05-29 Board Of Trustees Of The University Of Arkansas Monoclonal antibodies that selectively recognize methamphetamine and methamphetamine like compounds
CN101597233A (en) * 2008-04-15 2009-12-09 曾立波 Not with the methyl amphetamine monoclonal antibody kit of ephedrine and pseudoephedrine cross reaction
US20140271686A1 (en) * 2013-03-13 2014-09-18 Board Of Trustees University Of Arkansas Anti-(+) -methamphetamine monoclonal antibodies

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0311383A2 (en) * 1987-10-09 1989-04-12 Ube Industries, Ltd. Monoclonal antibody to methamphetamine, preparation of the same, assay method and assay kit of methamphetamine
CN1179469A (en) * 1996-10-11 1998-04-22 财团法人生物技术开发中心 Monoclonal antibody of p-methyl benzedrine with specificity, hybridoma producing same and kit containing monoclonal antibody and its use
CN1410770A (en) * 2002-11-22 2003-04-16 上海凯创生物技术有限公司 Reagent box for fast detecting methyl amphetamine and its preparation process
US20080125579A1 (en) * 2006-06-15 2008-05-29 Board Of Trustees Of The University Of Arkansas Monoclonal antibodies that selectively recognize methamphetamine and methamphetamine like compounds
CN101597233A (en) * 2008-04-15 2009-12-09 曾立波 Not with the methyl amphetamine monoclonal antibody kit of ephedrine and pseudoephedrine cross reaction
US20140271686A1 (en) * 2013-03-13 2014-09-18 Board Of Trustees University Of Arkansas Anti-(+) -methamphetamine monoclonal antibodies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ERIC C. PETERSON: "Using Hapten Design to Discover Therapeutic Monoclonal Antibodies for Treating Methamphetamine Abuse", THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 322, no. 1, pages 30 - 39, XP002579864, DOI: 10.1124/jpet.106.117150 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117088983A (en) * 2022-05-11 2023-11-21 东莞市朋志生物科技有限公司 Anti-amphetamine antibodies, reagents and kits for detecting amphetamine
CN117088983B (en) * 2022-05-11 2024-03-12 东莞市朋志生物科技有限公司 Anti-amphetamine antibodies, reagents and kits for detecting amphetamine

Similar Documents

Publication Publication Date Title
CN116693676B (en) Anti-mycoplasma pneumoniae antibody, reagent for detecting mycoplasma pneumoniae and kit
CN115197316B (en) Antibodies against novel coronaviruses, reagents and kits for detecting novel coronaviruses
CN117088982A (en) Anti-methamphetamine antibodies, reagents and kits for detecting methamphetamine
CN116444657B (en) Antibodies against novel coronaviruses, reagents and kits for detecting novel coronaviruses
CN117088983B (en) Anti-amphetamine antibodies, reagents and kits for detecting amphetamine
CN117229409B (en) Anti-phencyclidine antibody, reagent for detecting phencyclidine and kit
CN116444656B (en) Antibody, reagent and method for identifying novel crown mutant antigen
CN116836273B (en) Anti-serum amyloid A antibody, reagent for detecting serum amyloid A and kit
CN116836279B (en) Anti-tetraiodothyroxine antibody, reagent and kit for detecting tetraiodothyroxine
CN117285638A (en) Anti-buprenorphine antibodies, reagents and kits for the detection of buprenorphine
CN116693683B (en) Anti-testosterone antibody, reagent for detecting testosterone and kit
CN117285639B (en) Anti-ethyl glucuronide antibody, and reagent and kit for detecting ethyl glucuronide
CN117229408A (en) Anti-barbital compound antibody, reagent for detecting barbital drugs and kit
CN116496401B (en) Anti-abnormal prothrombin antibody, reagent for detecting abnormal prothrombin and kit
CN116836271B (en) Antibodies against type B streptococcus, reagents and kits for detecting type B streptococcus
CN116836278B (en) Anti-progesterone antibody, kit for detecting progesterone
CN116836274A (en) Anti-serum amyloid A antibody, reagent for detecting serum amyloid A and kit
CN117285639A (en) Anti-ethyl glucuronide antibody, and reagent and kit for detecting ethyl glucuronide
CN116925216A (en) Anti-serum amyloid A antibody, reagent for detecting serum amyloid A and kit
CN117229409A (en) Anti-phencyclidine antibody, reagent for detecting phencyclidine and kit
CN117088975A (en) Anti-albumin antibody, reagent and kit for detecting albumin
CN116693678B (en) Anti-mycoplasma pneumoniae antibody, reagent for detecting mycoplasma pneumoniae and kit
CN116836277B (en) Anti-estradiol antibody, reagent for detecting estradiol and kit
CN117088984A (en) Anti-benzodiazepine antibody, and kit and reagent for detecting benzodiazepine
CN117659201A (en) Anti-cocaine antibodies or functional fragments thereof, reagents and kits for detection of cocaine

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination